Molecular Pharming for low and middle income countries

Current Opinion in Biotechnology

Volumn 61, Issue , 2020, Pages 53-59

  Murad, Sheeba ^a   Fuller, Sebastian ^a   Menary, Jonathan ^a   Moore, Cathy ^a   Pinneh, Elizabeth ^a   Szeto, Tim ^a   Hitzeroth, Inga ^b   Freire, Marcos ^c   Taychakhoonavudh, Suthira ^d   Phoolcharoen, Waranyoo ^d   Ma, Julian K C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Instituto de Technologia em Imunobiologicos   (Brazil)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC COMMUNITY; ACADEMIC RESEARCH; DEVELOPED COUNTRIES; EXTERNAL FACTORS; LOW AND MIDDLE INCOME COUNTRIES; MANUFACTURING CAPACITY; RESEARCH EFFORTS; SOUTH AFRICA;

BIOTECHNOLOGY;

BRAZIL; DEVELOPED COUNTRY; FEASIBILITY STUDY; INVESTMENT; MIDDLE INCOME COUNTRY; MOLECULAR FARMING; REVIEW; SOUTH AFRICA; THAILAND; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY;

COMMERCE; DEVELOPING COUNTRIES; MOLECULAR FARMING;

EID: 85074994662     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2019.10.005     Document Type: Review

References (32)

1. Ma, J.K.C., Barros, E., Bock, R., Christou, P., Dale, P.J., Dix, P.J., Fischer, R., Irwin, J., Mahoney, R., Pezzotti, M., et al. Molecular farming for new drugs and vaccines - current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep 6 (2005), 593–599.
2. Arntzen, C., Plant-made pharmaceuticals: from’ Edible Vaccines’ to Ebola therapeutics. Plant Biotechnol J 13 (2015), 1013–1016.
3. Group PIW, Multi-National PIIST, Davey, R.T. Jr., Dodd, L., Proschan, M.A., Neaton, J., Neuhaus Nordwall, J., Koopmeiners, J.S., Beigel, J., Tierney, J., et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 375 (2016), 1448–1456.
4. Cohen, J.P., Silva, L., Cohen, A., Awatin, J., Sturgeon, R., Progress report on neglected tropical disease drug donation programs. Clin Ther 38 (2016), 1193–1204.
5. Rappuoli, R., Miller, H.I., Falkow, S., The intangible value of vaccination. Science 297 (2002), 937–939.
6. Ma, J.K., Christou, P., Chikwamba, R., Haydon, H., Paul, M., Ferrer, M.P., Ramalingam, S., Rech, E., Rybicki, E., Wigdorowitz, A., et al. Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies. Plant Biotechnol J 11 (2013), 1029–1033.
7. Surichan, S., Wirachwong, P., Supachaturas, W., Utid, K., Theerasurakarn, S., Langsanam, P., Lakornrach, P., Nitisaporn, L., Chansikkakorn, C., Vangkanonta, W., et al. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Vaccine 29:Suppl. 1 (2011), A29–33.
8. Rattanapisit, K., Abdulheem, S., Chaikeawkaew, D., Kubera, A., Mason, H.S., Ma, J.K., Pavasant, P., Phoolcharoen, W., Recombinant human osteopontin expressed in Nicotiana benthamiana stimulates osteogenesis related genes in human periodontal ligament cells. Sci Rep, 7, 2017, 17358 A Molecular Pharming paper led by Thai researchers from a Thai funded research project that supported a local area of research strength. Osteopontin is a bone matrix protein with multiple properties that could enhance osteogenesis.
9. Kim, M.Y., Copland, A., Nayak, K., Chandele, A., Ahmed, M.S., Zhang, Q., Diogo, G.R., Paul, M.J., Hofmann, S., Yang, M.S., et al. Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties. Plant Biotechnol J 16 (2018), 1283–1294 An important advance in developing a new vaccine platform in plants, in this case for a dengue vaccine. The platform is based on vaccine antigen displayed by multimerised immunoglobulin Fc which allows for self adujvantation through direct targeting of Fc receptors on antigen presenting cells.
10. Kim, M.Y., Van Dolleweerd, C., Copland, A., Paul, M.J., Hofmann, S., Webster, G.R., Julik, E., Ceballos-Olvera, I., Reyes-Del Valle, J., Yang, M.S., et al. Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate. Plant Biotechnol J 15 (2017), 1590–1601.
11. Chen, T.H., Hu, C.C., Liao, J.T., Lee, Y.L., Huang, Y.W., Lin, N.S., Lin, Y.L., Hsu, Y.H., Production of Japanese encephalitis virus antigens in plants using bamboo mosaic virus-based vector. Front Microbiol, 8, 2017, 788.
12. Webster, G.R., van Dolleweerd, C., Guerra, T., Stelter, S., Hofmann, S., Kim, M.Y., Teh, A.Y., Diogo, G.R., Copland, A., Paul, M., et al. A polymeric immunoglobulin - antigen fusion protein strategy for enhancing vaccine immunogenicity. Plant Biotechnol J 16 (2018), 1983–1996.
13. Pillet, S., Couillard, J., Trepanier, S., Poulin, J.F., Yassine-Diab, B., Guy, B., Ward, B.J., Landry, N., Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-two randomized Phase II clinical trials in 18 to 49 and >/=50 years old adults. PLoS One, 14, 2019, e0216533 Latest report on progress with plant produced influenza vaccine. Two clinical trials report on the safety and immunogenicity of a quadrivalent VLP candidate flu vaccine in two groups of patients’ 18–49 years old and ≥50 years old subjects.
14. Rybicki, E.P., Chikwamba, R., Koch, M., Rhodes, J.I., Groenewald, J.H., Plant-made therapeutics: an emerging platform in South Africa. Biotechnol Adv 30 (2012), 449–459.
15. Mbewana, S., Meyers, A.E., Weber, B., Mareledwane, V., Ferreira, M.L., Majiwa, P.A.O., Rybicki, E.P., Expression of Rift Valley fever virus N-protein in Nicotiana benthamiana for use as a diagnostic antigen. BMC Biotechnol, 18, 2018, 77 This paper reports chimaeric RVFV virus-like particles transiently expressed in Nicotiana benthamiana at high levels, which are immunogenic in mice. Rift Valley fever is an important emerging infection which causes abortion endemics in farmed animals and potentially causes miscarriages in humans.
16. Margolin, E., Chapman, R., Williamson, A.L., Rybicki, E.P., Meyers, A.E., Production of complex viral glycoproteins in plants as vaccine immunogens. Plant Biotechnol J, 2018 [Epub ahead of print].
17. Veerapen, V.P., van Zyl, A.R., Wigdorovitz, A., Rybicki, E.P., Meyers, A.E., Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana. Virus Res 244 (2018), 213–217.
18. Dennis, S.J., O'Kennedy, M.M., Rutkowska, D., Tsekoa, T., Lourens, C.W., Hitzeroth, I.I., Meyers, A.E., Rybicki, E.P., Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses. Vet Res, 49, 2018, 105 Having previously reported African horse sickness virus-like particle production in plants, this follow–on paper describes safety and immunogenicity of plant-produced AHS VLPs in horses. African horse sickness (AHS) is a highly contagious, notifiable disease in domestic horses in sub-Saharan Africa.
19. van Dolleweerd, C.J., Teh, A.Y., Banyard, A.C., Both, L., Lotter-Stark, H.C., Tsekoa, T., Phahladira, B., Shumba, W., Chakauya, E., Sabeta, C.T., et al. Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody. J Infect Dis 210 (2014), 200–208.
20. Tsekoa, T.L., Lotter-Stark, T., Buthelezi, S., Chakauya, E., Stoychev, S.H., Sabeta, C., Shumba, W., Phahladira, B., Hume, S., Morton, J., et al. Efficient in vitro and in vivo activity of glyco-engineered plant-produced rabies monoclonal antibodies E559 and 62-71-3. PLoS One, 11, 2016, e0159313.
21. Tschofen, M., Knopp, D., Hood, E., Stoger, E., Plant molecular farming: much more than medicines. Annu Rev Anal Chem 9 (2016), 271–294.
22. Romano, A.P., Costa, Z.G., Ramos, D.G., Andrade, M.A., Jayme Vde, S., Almeida, M.A., Vettorello, K.C., Mascheretti, M., Flannery, B., Yellow Fever outbreaks in unvaccinated populations, Brazil, 2008–2009. PLoS Negl Trop Dis, 8, 2014, e2740.
23. Spok, A., Twyman, R.M., Fischer, R., Ma, J.K., Sparrow, P.A., Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol 26 (2008), 506–517.
24. Geels, F.W., Schot, J., Typology of sociotechnical transition pathways. Res Policy 36 (2007), 399–417.
25. Owen, R., Macnaghten, P., Stilgoe, J., Responsible research and innovation: From science in society to science for society, with society. Sci Public Policy 39 (2012), 751–760.
26. Cornwall, A., Jewkes, R., What is participatory research (vol 41, pg 1667, 1995). Soc Sci Med, 70, 2010, 794.
27. Mebane, F., Blendon, R.J., Political strategy 101: how to make health policy and influence political people. J Child Neurol 16 (2001), 513–519.
28. Malyska, A., Bolla, R., Twardowski, T., The role of public opinion in shaping trajectories of agricultural biotechnology. Trends Biotechnol 34 (2016), 530–534.
29. Aluttis, C., Krafft, T., Brand, H., Global health in the European Union - a review from an agenda-setting perspective. Global Health Action 7 (2014), 1–6.
30. Callaway, E., CRISPR plants now subject to tough GM laws in European Union. Nature, 560, 2018, 16.
31. Zimny, T., Sowa, S., Tyczewska, A., Twardowski, T., Certain new plant breeding techniques and their marketability in the context of EU GMO legislation - recent developments. Nat Biotechnol 51 (2019), 49–56 An analysis of the EU's legal classification of new plant breeding techniques, including gene editing, in the light of the European Court of Justice recent ruling (Case C-528/16). The legal and practical landscape of GMO regulation in Europe is explained, and the impact this will have on GMO adoption in a global context is reviewed.
32. Faye, L., Gomord, V., Success stories in molecular farming-a brief overview. Plant Biotechnol J 8 (2010), 525–528.